+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and lasting effects of a single intravitreal injection of 4D-150 compared to aflibercept in adults with diabetic macular edema DME. The study is a Phase 3, randomized, double-masked, active-controlled trial designed to assess visual acuity changes and disease severity over one year. Participants will be randomly assigned to receive either a single dose of 4D-150 or aflibercept eye injections. The 4D-150 treatment is given once on Day 1, while aflibercept is administered at appropriate visits. The study lasts for 52 weeks, focusing on visual outcomes and the need for additional aflibercept injections after the initial treatments. Throughout the study, participants will undergo regular eye examinations to monitor visual acuity using the Early Treatment Diabetic Retinopathy Study ETDRS scale and assessments of diabetic retinopathy severity. Researchers will also track the number of aflibercept injections needed after Week 4. Safety and durability of the treatments will be closely observed during the one-year follow-up period.

Age: 18Years +All GendersPhase 3
87 locations
S

Actively Recruiting

Macular dystrophies are inherited eye conditions that affect the macula, the central part of the retina responsible for detailed vision. Stargardt disease STGD and STGD-like macular dystrophies cause gradual loss of central vision, usually starting in childhood or adolescence. This early development study evaluates the safety and tolerance of ASP2020, a stem cell treatment designed to replace damaged cells in people with STGD-type macular dystrophies. ASP2020 consists of human stem cells transformed into macular cells and is given as a single injection under the retina via surgery performed under general anesthesia. After the injection, a steroid is administered into the eye to reduce swelling. The study is divided into two parts Part 1 tests low and high doses in adults and teenagers with a 6-month gap between groups to monitor safety, while Part 2 treats adults, teenagers, and children with the optimal dose determined from Part 1. Participants stay in the study for about one year with multiple clinic visits for safety monitoring and various eye exams including imaging and blood tests. Researchers will track adverse events, immune responses, and changes in vision and retinal health using several specific tests to assess the impact of ASP2020 and ensure participant safety throughout the study.

Age: 6Years +All GendersPhase 1
4 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
S

Actively Recruiting

Researchers are investigating a potential treatment called ASP7317 for people with geographic atrophy caused by dry age-related macular degeneration AMD, an eye disease that gradually reduces sharp central vision, making daily activities like reading and driving challenging. This open-label Phase 1b study aims to evaluate the safety and tolerability of ASP7317, which consists of human stem cells transformed into retinal cells, injected under the macula to possibly replace damaged cells and improve vision. The trial includes older adults with either severe or moderate vision loss due to geographic atrophy. Participants will receive one of three doses of ASP7317low, medium, or highadministered via subretinal injection under local or general anesthesia. To prevent rejection, participants take tacrolimus tablets starting days before the injection and continuing for several weeks after, along with other medications to prevent infections. The study is divided into two groups based on vision loss severity, with small cohorts receiving escalating doses sequentially. An independent medical panel monitors safety after each dose before proceeding to the next group or dose level. During the 52-week study period following treatment, participants will attend several clinic visits for health monitoring and eye examinations. These include vital sign checks, blood tests, eye imaging, and vision assessments. Researchers will track safety through adverse events and signs of graft rejection, while also measuring changes in geographic atrophy area and visual function. Extra clinic visits may occur if needed, and the total time involved includes up to 60 days of screening followed by one year of post-treatment observation.

Age: 50Years +All GendersPhase 1
20 locations
E

Actively Recruiting

Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.

Age: 18Years - 80YearsAll GendersPhase 4
101 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
O

Actively Recruiting

Macular dystrophies are inherited eye conditions affecting the macula, the central part of the retina responsible for detailed vision. Stargardt disease STGD is a common type caused by mutations in the ABCA4 gene, leading to progressive vision loss mainly in childhood or adulthood. This study aims to understand and compare how STGD and similar macular dystrophies progress over time by observing patients with these conditions. Participants in this observational study will continue their usual care managed by their doctors. They will visit the clinic every six months for up to two years to undergo standard eye exams and imaging tests. The study collects information on participants health, medications, supplements, and daily activities. If available, medical records and imaging data from the previous two years will also be reviewed to provide a comprehensive picture of disease progression. During the study, participants will have their vision measured through tests like best corrected visual acuity at baseline and every six months. Other assessments include reading ability, retinal thickness, and retinal layer integrity using imaging techniques. Researchers will monitor changes in these measures to understand disease progression. The study lasts up to 24 months, with visits every six months for assessments and data collection about participants vision and overall wellbeing.

Age: 6Years +All Genders
15 locations
C

Actively Recruiting

Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.

Age: 18Years +All GendersPhase 2
90 locations
E

Actively Recruiting

Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.

Age: 18Years +All Genders
491 locations

1-10 of 17

1